natgillin/translations-raw huggingface dataset:
28 tabletter: EU/1/10/632/009
28 tablets: EU/1/10/632/009
28 tabletter: EU/1/10/632/016
28 tablets: EU/1/10/632/016
28 tabletter: EU/1/11/721/002
28 tablets: EU/1/11/721/002
28 tabletter: EU/1/11/721/009
28 tablets: EU/1/11/721/009
28 tabletter: EU/1/11/721/016
28 tablets: EU/1/11/721/016
28 tabletter: EU/1/11/723/002
28 tablets: EU/1/11/723/002
28 tabletter: EU/1/11/723/009
28 tablets: EU/1/11/723/009
28 tabletter: EU/1/11/723/016
28 tablets: EU/1/11/723/016
28 ud af de 231 patienter (12,1%) på vandetanib og 3 ud af de 99 (3,0%) på placebo seponerede behandlingen på grund af en bivirkning.
Twenty-eight of the 231 patients (12.1%) on vandetanib and 3 of the 99 (3.0%) on placebo discontinued treatment because of an adverse event.
28 uger
52 weeks
28 x 1 kapsler
28 x 1 capsules (unit
28 x 1 smeltetablet
28 x 1 orodispersible tablet
28 x 1 smeltetablet: EU/1/09/525/027
28 x 1 orodispersible tablet:EU/1/09/525/027
28 x 1 smeltetablet: EU/1/09/525/032
28 x 1 orodispersible tablet:EU/1/09/525/032
28 x 1 smeltetablet: EU/1/09/525/037
28 x 1 orodispersible tablet:EU/1/09/525/037
28 x 1 smeltetablet: EU/1/09/525/042
28 x 1 orodispersible tablet:EU/1/09/525/042
28 x 1 smeltetabletter
28 x 1 orodispersible tablets
28 x 1 smeltetabletter x 1 smeltetabletter
28 x 1 orodispersible tablets x 1 orodispersible tablets
28 x 1 tablet (dosisenhed)
28 x 1 tablets (unit dose)
28 x 1 tablet (enhedsdosis)
28 x 1 tablet (unit dose)
28 x 1 tablet (enkeltdosis)
28 x 1 tablet (unit dose)
28 x 1 tablet (enkeltdosisblister)
28 x 1 tablet (unit dose)
28 x 1 tablet (enkeltstyk)
28 x 1 tablet (unit dose)
28 X 1 tabletter
28 x 1 tablet
28 x 1 tabletter
28 x 1 tablets (unit
28 x 1 tabletter (enhedsdosis)
28 x 1 tablets (unit dose)
28 x 1 tabletter (enhedsdosis)
28x1 tablets (unit dose)
28 x 1 tabletter (enkeltdosis)
28 x 1 tablets (unit dose)
28 x 10 kapsler + 2 inhalatorer
28 x 10 capsules + 2 inhaler
28 x 1tabletter
28 x 1 tablets
28 x1 tabletter
28 x 1 tablets
28 g
28 µg
28%*
Placebod
28, 30, 40, 50, 60, 90, 100 og 105 filmovertrukne tabletter og i perforerede enkeltdosisblisterpakninger med 50 x 1 filmovertrukket tablet (enkeltdosispakning).
60, 90, 100 and 105 film-coated tablets and in perforated blister packs of 50 x 1 film-coated tablet (unit dose).
28, 56 eller 112 kapsler i transparente PVC/Alu-blistere til udtrykning
28, 56 or 112 capsules in transparent PVC/Alu push through blisters
28,0% (13,3-42,6)
28.0% (13.3, 42.6) p=0.0004
28,1 %
NA
28,2 l/min.
28.2L/min
28,3 mg/tablet
28.3 mg/tablet
28,6 % (forsøg MN301) og 49,4 % vs.
28.6 % (study MN301), and 49.4 % vs.
28,6% (forsøg MN301) og 49,4% versus.
28.6% (study MN301), and 49.4% vs.
28,6% (forsøg MN301) og 49,4% vs.
28.6 % (study MN301), and 49.4 % vs.
28,8 %
NA
28,9 (11,9;
N/Ac 28.9 (11.9,
28,9 til 30,6
28.9 to 30.6
28,9-37,1 måneder) for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin.
28.9-37.1 months) for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
28-dages pakning: 112 kapsler (4 blisterkort med 21 x 20 mg kapsler og 7 x 80 mg kapsler (140 mg/dag dosis til forsyning i 28 dage).
28 day pack: 112 capsules (4 blister cards of 21 x 20 mg capsules and 7 x 80 mg capsules) for the 140 mg daily dose for a 28 day supply.
28-dages pakning: 56 kapsler (4 blisterkort med 7 x 20 mg kapsler og 7 x 80 mg kapsler) (100 mg/dag dosis til forsyning i 28 dage).
28 day pack: 56 capsules (4 blister cards of 7 x 20 mg capsules and 7 x 80 mg capsules) for the 100 mg daily dose for a 28 day supply.
28-dages pakning: 84 kapsler (4 blisterkort med 21 x 20 mg kapsler) (60 mg/dag dosis til forsyning i 28 dage).
28 day pack: 84 capsules (4 blister cards of 21 x 20 mg capsules) for the 60 mg daily dose for a 28 day supply.
28. august 2015
28 August 2015
28. juli 2009
28 July 2009
28.163 Jevany Tjekkiet
28163 Jevany Czech Republic
280 (20 x 14) tabletter (multipakning)
280 (20 x 14) tablets (multipack)
280 (20 x 14) tabletter (multipakning)
tablet (multipack) 280 (20 x 14)
280 (20x14) tabletter
280 (20x14) tablets
280 (20x14) tabletter (multipakning)
280 (20x14) tablets (multipack)
280 tabletter
280 tablets
280 tabletter (20 x 14)
280 tablets (20 x 14)
280 tabletter (20x14, PA/Alu/PVC blister)
280 tablets (20x14, PA/Alu/PVC blisters)
280 tabletter (20x14, PVC/PCTFE blister)
280 tablets (20x14, PVC/PCTFE blisters)
280 tabletter (4 x 70)
280 tablets (4 x 70)
280 tabletter (multipakning)
280 tablets (multipack)
280 x 1 (4 x 70) tablet (multipakning)
280 x 1 (4 x 70)
280 x 1 tablet (enhedsdosis)
280 x 1 tablet (unit dose)
280 x 1 tablet (enhedsdosis)
280 x 1 tablets (unit dose)
2800 IE
2800 IU
28023 (Avravaca) Madrid Espana
28023 (Aravaca) Madrid España
28108 Madrid Spanien
28108 Madrid Spain
2870 Puurs Belgien
B-2870 Puurs Belgium
2870 Puurs Belgien
B-2870 Puurs Belgium‌
2870 Puurs Belgien
B-2870 Puurs,
28760 Madrid (SPANIEN)
28760 Madrid (SPAIN)
28760 Madrid SPANIEN
28760 Madrid SPAIN
28770 Colmenar Viejo (Madrid) Spanien
28770 Colmenar Viejo (Madrid) Spain
288 celler/mm³ og gennemsnitsbaseline hiv-RNA i plasme var 5,21 log10 kopier/ml (160.394 kopier/ml).
288 cells/mm3 and the mean baseline plasma HIV RNA was 5.21 log10 copies/ml (160,394 copies/ml).
288 t
288 h
2880 Bagsværd Danmark
DK-2880 Bagsværd Denmark
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - Frankrig
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - France
28830 San Fernando de Henares (Madrid) Tel: +34 91 669 93 00
E-28830 San Fernando de Henares (Madrid) Tel: +34 91 669 93 00
289 (46,0%) ng/ml og 2.310 (43,5%) ng•t/ml hos probander med moderat nedsat leverfunktion og 305 (24,8%) ng/ml og 2.740 (44,0%) ng•t/ml hos probander med svært nedsat leverfunktion.
289 (46.0%) ng/mL and 2,310 (43.5%) ng•h/mL in subjects with moderate hepatic impairment, and 305 (24.8%) ng/mL and 2,740 (44.0%) ng•h/mL in subjects with severe hepatic impairment.
28; MTX 15 mg intrathecal, dag 1, 8, 15, 22;
MTX 15 mg intrathecal, days 1, 8, 15, 22;
28x1 filmovertrukne tabletter
100x1 film-coated tablets 28x1 film-coated tablets
28x1 tabletter
28x1 tablets
29 % (44 ud af 154) af dem, der fik Ikervis, sammenholdt med 23 % (21 ud af 91) af dem, der fik vehiklet.
About 29% (44 of 154) of those given Ikervis responded, compared with 23% (21 of 91) given the vehicle.
29 af de 39 forsøgspersoner, som fik placebo, gennemførte 24 måneders behandling med Revestive.
Of the 39 placebo subjects, 29 completed 24 months of treatment with Revestive.
29 avenue Tony Garnier 69007 Lyon
29, avenue Tony Garnier 69007 Lyon
29 avenue Tony Garnier 69007 LYON FRANKRIG
29 avenue Tony Garnier F-69007 LYON FRANCE
29 avenue Tony Garnier 69007 Lyon, Frankrig
29 avenue Tony Garnier 69007 Lyon, France
29 avenue Tony Garnier F-69007 Lyon
29 avenue Tony Garnier 69007 LYON
29 avenue Tony Garnier F-69007 LYON FRANKRIG
29 avenue Tony Garnier F-69007 LYON FRANCE
29 avenue Tony Garnier FR-69007 Lyon
29, Avenue Tony Garnier FR-69007 LYON
29 Avenue Tony Garnier, 69007 Lyon,
29 Avenue Tony Garnier 69007 Lyon
29 b
29b
29 IE/kg
29 IU/kg (13;
29 route des Industries 37530 Pocé-sur-Cisse Frankrig
29 route des Industries 37530 Pocé-sur-Cisse France
29 til < 32
29 to < 32
29% regionalt avanceret prostatakræft
29% had locally advanced prostate cancer
29,2 % versus 66,7 %, p = 0,017).
66.7% respectively, p = 0.017).
29,2 % versus 66,7 %, p = 0,017).
66.7% respectively, p=0.017).
29,2 % versus 66,7 %, p=0,017).
66.7% respectively, p=0.017).
29,2 – 30,8 kg
29.2 - 30.8 kg
29,4 (24,5-IE)
29.4 (24.5, NE)
29,6 til 36,1
29.6 to 36.1
29,7
HVL
29,8 (20,2; 44,1)
GMT (95%CI)
29-41 kg
29 – 41 kg
29. november 2010
29 November 2010
290 mikrogram
290 micrograms
290 mikrogram pr. dag med hyppigheder svarende til: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til < 1/100), sjælden (≥ 1/10.000 til < 1/1.000) og meget sjælden (<1/10.000) ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
290 micrograms per day with frequencies corresponding to: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to < 1/1,000) and very rare (<1/10,000) and not known (cannot be estimated from the available data).
290 mikrogram/dag hos 18 raske frivillige blev cirka 3 - 5 % af dosis genfundet i afføringen, stort set alt sammen som den aktive des-tyrosin metabolit.
290 micrograms/day in 18 healthy volunteers, approximately 3 to 5% of the dose was recovered in the faeces, virtually all of it as the des-tyrosine active metabolite.
294 (3x98) tabletter (multipakning)
294 (3x98) tablets (multipack)
294 tabletter
294 tablets
297 Filmovertrukne tabletter.
297 film-coated tablets
297 tabletter
297 tablets
2970 Hørsholm Danmark eller
2970 Hørsholm Denmark or
2: de fleste tilfælde af unormal leverfunktion/leversygdom rapporteret for telmisartan efter markedsføringen forekom hos japanske patienter.
2: most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in Japanese patients.
2: For yderligere beskrivelse, se underafsnittet ”Beskrivelse af udvalgte bivirkninger”
2: For further description, please see sub-section “Description of selected adverse reactions”
2: Kontrolvindue
2: Viewing window
2: Stempelhoved
2: Plunger head
2: æg infektiøs dosis 50%
2: egg infective dose 50
2: ”Kontrol af din EXJADE-behandling”).
Monitoring your EXJADE treatment”).
2a Klik den blå port åben.
2a Snap open Blue port.
2adjuveret med AS04 indeholdende:
2adjuvanted by AS04 containing:
2adsorberet på AlPO4 0,2 miligram Al3+
2adsorbed on AlPO4 0.2 milligrams Al3+
2adsorberet på aluminiumhydroxid, hydreret 0,05 milligram Al3+ 3produceret på gærceller (Saccharomyces cerevisiae) ved rekombinant DNA-teknologi 4adsorberet på aluminiumphosphat 0,4 milligram Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al3+
2adsorberet på aluminiumhydroxidhydrat (Al(OH) ) 0,5 milligram Al3+ totalt
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
2adsorberet på aluminiumphosphat (0,5 mg Al3+ totalt)
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorberet på aluminiumphosphat (0,5 milligram Al3+ totalt)
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorberet til aluminiumfosfat Total: 0.40 mg Al3+ 3Fremstillet i Saccharomyces cerevisae celler vha. rekombinant DNA teknologi.
3 produced in Saccharomyces cerevisae cells by recombinant DNA technology
2Adsorberet til aluminiumhydroxidhydrat 0,05 milligram Al3+ 3Produceret i gærceller (Saccharomyces cerevisiae) ved rekombinant DNA-teknologi 4Adsorberet til aluminiumphosphat 0,4 milligram Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate, 0.4 milligrams Al3+
2Adsorberet til aluminiumhydroxidhydrat 0,05 milligram Al3+ 3Produceret på gærceller (Saccharomyces cerevisiae) ved rekombinant DNA teknologi 4Adsorberet til aluminumphosphat 0,4 milligram Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al3+
2adsorberet til aluminiumphosphat (0,5 milligram Al3+ totalt)
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2Baseret på logistisk regression.
2Based on a logistic regression.
2Bendamustin gives intravenøst på 1. og 2. behandlingsdag i alle behandlingsserier (serie 1-6) i en dosis på 90 mg/m2/dag
2 Bendamustine is given intravenously on Days 1 and 2 of all treatment cycles (Cycles 1-6) at 90 mg/m2/day
2Bivirkning forekom både i behandlingsfasen og på screeningsdagen
2Adverse reaction occurred both during the treatment phase and on the day of screening
2c Udtag nøjagtigt 19 ml af opløsningen og afmontér sprøjten.
2c Withdraw exactly 19 mL of the solution and unscrew the syringe.
2D-stregkode med det unikke id.
2D barcode carrying the unique identifier included.
2Enkeltstående tilfælde rapporteret efter markedsføringen.
2 Isolated cases reported in post-marketing experience
2firdobbelt stigning af serum-neutraliserende antistof-titer
2 4-fold increase in serum neutralising antibody titre
2g Knæk!
2g Snap
2Gennemsnitlig forøgelse i fastende lipidtal (total kolesterol, LDL kolesterol og triglycerider) var højere hos patienter uden tegn p å lipiddysregulering ved baseline.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2Gennemsnitlig forøgelse i fastende lipidtal (total-kolesterol, LDL kolesterol og triglycerider) var højere hos patienter uden tegn p å lipiddysregulering ved baseline.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2Gennemsnitlig forøgelse i fastende lipidtal (totalt kolesterol, LDL- kolesterol og triglycerider) var højere hos patienter uden tegn på lipiddysregulering ved baseline.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2Halvtreds procent af forsøgspersonerne tog insulin som monoterapi ved baseline; 50 % tog 1 eller 2 orale glucosesænkende lægemidler i tilgift til insulin: i denne sidste gruppe tog 80 % kun metformin, 12 % tog metformin plus sulfonylurinstofbehandling, og resten tog andre orale glucosesænkende lægemidler.
2Fifty percent of subjects were on insulin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products.
2Halvtreds procent af forsøgspersonerne tog insulin som monoterapi ved baseline; 50 % tog 1 eller 2 orale glucosesænkende lægemidler i tilgift til insulin: i denne sidste gruppe tog 80 % kun metformin, 12 % tog metformin plus sulfonylurinstofbehandling, og resten tog andre orale glucosesænkende lægemidler.
lin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products.
2Kun ved den initiale kombinationsbehandling.
2Only in the initial combination therapy.
2kun ved initial kombinationsbehandling.
2 Only in the initial combination therapy.
2L1 protein i form af viruslignende partikler dannet i gærceller (Saccharomyces cerevisiae
2L1 protein in the form of virus like particles produced in yeast cells (Saccharomyces cerevisiae
2Middelværdi korrigeret for baseline-HbA1c, baseline-eGFR, geografisk område og antal antihypertensiva.
2 Mean adjusted for baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products
2p-værdien er udledt fra ANCOVA t-test.
2 p-value is derived from ANCOVA t-test.
2PFU = Plaqueformende enheder
2PFU = Plaque-forming units
2Som nedre konfidensgrænse (p= 0,95)
2 As lower confidence limit (p = 0.95)
2Termen “abdominalsmerter" omfatter: abdominalsmerter, nedre abdominalsmerter og øvre abdominalsmerter.
2“Abdominal pain" term includes: abdominal pain, abdominal pain lower, and abdominal pain upper.
2Vaccinens effekt
2Vaccine efficacy
2x karton for blisterpakning der indeholder 150 mg maraviroc filmovertrukne tabletter
2x carton for blister pack containing 150 mg maraviroc film-coated tablets
2x karton for blisterpakning der indeholder 300 mg maraviroc filmovertrukne tabletter
2x carton for blister pack containing 300 mg maraviroc film-coated tablets
2x1 dosis 20x1 dosis
2x1 dose 20x1 dose
2æg infektiøs dosis 50%.
2 egg infective dose 50
3 "Vejledning i brug til voksne (> 18 år)". antacida (bruges til behandling af sygdomme forårsaget af for meget mavesyre; f.eks. aluminium-/magnesiumhydroxid, calciumcarbonat).
antacids (used to treat diseases related to the acid in the stomach; for example, aluminium / magnesium hydroxide, calcium carbonate).
3 %
3% (v/v)
3 % (3/91)d
3% (3/91)d
3 % (n=236)
3% (n=236)
3 % af patienterne (18/681) udviklede persisterende antistoffer mod PEG-fraktionen af peginterferon beta-1a.
3% of patients (18/681) developed persistent antibodies to the PEG moiety of peginterferon beta-1a.
3 % aluminiumhydroxidgel udtrykt som mg Al 1 mg
3% aluminium hydroxide gel expressed as mg Al3+ 1 mg
3 % aluminiumhydroxidgel udtrykt som mg Al 1 mg
3% aluminium hydroxide gel expressed as mg Al3+: 1 mg
3 % aluminiumhydroxidgel udtrykt som mg Al3+ 1 mg
3% aluminium hydroxide gel expressed as mg Al3+: 1 mg
3 % og 5 % vs.
3% and 5% vs.
3 % vægttab pr. måned = 0,7 % pr. uge = 0,1 % pr. dag
3% bodyweight loss per month = 0.7% per week = 0.1% per day
3 (0,8)
Balance disorder
3 (1,7)
Motor dysfunction
3 (3 x 1) forfyldt pen (multipakke)
3 (3 x 1) pre-filled pens (multipack)
3 (3 x 1) forfyldt sprøjte (multipakke)
3 (3 x 1) pre-filled syringes (multipack)
3 (3 x 1) fyldte penne (multipakning)
Multipack: 3 (3 packs of 1) pre-filled pens.
3 (3 x 1) fyldte sprøjter (multipakke)
3 (3x1) pre-filled syringe (multipack)
3 (3 x 1) fyldte sprøjter (multipakning)
Multipack: 3 (3 packs of 1) pre-filled syringes.
3 (3 x 1) hætteglas (multipakning)
3 (3 x 1) vials (multipack)
3 (3x1) fyldte injektionssprøjter
3 (3x1) pre-filled syringes
3 (3x1) fyldte penne
3 (3x1) pre-filled pens
3 (betinget)
3 (conditional)
3 - 23 måneder
3 to 23 months
3 - 6 år
3 - 6 years old
3 - 8 år
3 - 8 years
3 1.500 mg; Studie DUR001-303 forsøgspersoner med en farmakokinetisk evaluerbar prøve.
3 1500 mg; Study DUR001-303 subjects with evaluable PK sample.
3 3 – Tag fat i det hjørne, hvor forseglingen ikke klæber til folien, og træk folien på bagsiden tilbage for at tage resoribletten ud.
3 3 – Starting from the edge where the seal is lifted, pull back the foil on the back to remove the tablet
3 3 – Tag fat i det hjørne, hvor forseglingen ikke klæber til folien, og træk folien på bagsiden tilbage for at tage resoribletten ud.
3 3 – Starting from the edge where the seal is lifted, pull back the foil on the back to remove the tablet.
3 3,7 % af den samlede randomiserede patientpopulation havde stadium III B-sygdom.
3 3.7% of the overall randomised patient population had Stage IIIB disease.
3 3Fremstillet i Saccharomyces cerevisae celler vha. rekombinant DNA teknologi.
3 produced in Saccharomyces cerevisae cells by recombinant DNA technology
3 449 patienter med symtomatisk akut dyb ventrombose
3,449 patients with symptomatic acute deep vein thrombosis
3 5,8 % af den samlede randomiserede patientpopulation havde stadium III B sygdom.
3 5.8% of the overall randomised patient population had Stage IIIB disease.
3 89143 Blaubeuren Tyskland
3 89143 Blaubeuren Germany
3 95 % CI
3 95% CI
3 95 % konfidensinterval for one sample binomial ved brug af Pearson-Clopper metoden
3 95% CI for one sample binomial using Pearson-Clopper method
3 [1 hætteglas med pulver +
3 [1 powder vial
3 Adsorberet på amorf aluminiumhydroxyfosfat-sulfat-adjuvans (0,225 milligram Al)
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).
3 Adsorberet på amorf aluminiumhydroxyphosphat-sulfat-adjuvans (0,225 milligram Al)
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al).
3 af de 4 patienter fik forlænget behandlingen med 12 uger efter levertransplantationen, og 1 patient, der blev behandlet i 23 dage før transplantation, fik ikke forlænget behandlingen.
4 patients received 12 weeks of post-liver transplant treatment extension and 1 patient, treated for 23 days before transplantation, did not receive treatment extension.
3 af de testede efavirenz-behandlingssvigtisolater forblev følsomme over for efavirenz ved cellekultur og var også følsomme over for nevirapin og delavirdin.
Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine.
3 ampuller +
3 vials + 3 vials
3 antigen enheder
3 Antigen Units
3 anvendes til behandlingsdagene 13, 15 og 17
3 for treatment days 13, 15 and 17
3 Applikatorer
3 applicators
3 avenue George V FR-75008 Paris Frankrig
3 avenue George V FR-75008 Paris France
3 años.
3 years.
3 Baseret på en Cox' regressionsmodel.
3 Based on a Cox’s regression model.
3 Betaferon-hætteglas (med pulver til injektionsvæske, opløsning)
3 Betaferon vials (with powder for solution for injection)
3 Bivirkning identificeret for tenofovirdisoproxilfumarat.
3 Adverse reaction identified for tenofovir disoproxil fumarate.
3 Bivirkning observeret for mindst én af de individuelle komponenter, men ikke med Ultibro Breezhaler; hyppighedskategori jævnfør pkt.
3 Adverse reaction observed with at least one of the individual components, but not with Ultibro
3 Bivirkning observeret for mindst én af de individuelle komponenter, men ikke med Ulunar Breezhaler; hyppighedskategori jævnfør pkt.
3 Adverse reaction observed with at least one of the individual components, but not with Ulunar
3 Bivirkning observeret for mindst én af de individuelle komponenter, men ikke med Xoterna Breezhaler; hyppighedskategori jævnfør pkt.
3 Adverse reaction observed with at least one of the individual components, but not with Xoterna
3 Bivirkninger af metformin monoterapi.
3 Identified adverse reactions of metformin monotherapy
3 Bivirkninger identificeret i kliniske studier af emtricitabin+tenofoviralafenamid.
3 Adverse reactions identified from emtricitabine+tenofovir alafenamide clinical studies.
3 Bivirkninger indberettet i produktresuméet for mindst én af de individuelle komponenter, men indberettet med Brimica Genuair 340/12 mikrogram ved en forekomst, der var lavere end eller svarede til placebo.
3 Adverse reactions reported in the SmPC of at least one of the individual components, but reported with Brimica Genuair 340/12 micrograms at an incidence lower than or comparable to that of placebo.
3 Bivirkninger indberettet i produktresuméet for mindst én af de individuelle komponenter, men indberettet med Duaklir Genuair 340/12 mikrogram ved en forekomst, der var lavere end eller svarede til placebo.
3 Adverse reactions reported in the SmPC of at least one of the individual components, but reported with Duaklir Genuair 340/12 micrograms at an incidence lower than or comparable to that of placebo.
3 blistere à 1 mg må derfor ikke erstatte 1 blister à 3 mg (se afsnit 2, ” Vær særlig forsigtig med at anvende EXUBERA” og afsnit 3 ”Hvordan De tager EXUBERA”).
Three 1 mg blisters should not be substituted for one 3 mg blister (see section 2, “Take special care with EXUBERA” and section 3, “How to take EXUBERA”).
3 blistere à 1 mg må derfor ikke erstatte 1 blister à 3 mg (se afsnit 2, ” Vær særlig forsigtig med at anvende EXUBERA”, afsnit 3 ”Hvordan De tager EXUBERA” og afsnit 6 ”Yderligere oplysninger”).
Three 1 mg unit dose blisters should not be substituted for one 3mg blister (see section 2, “Take special care with EXUBERA”, section 3, “How to take EXUBERA” and section 6 “Further information”).
3 blisterkort (30 smeltetabletter)
3 blisters (30 oral lyophilisates)
3 blisterkort er pakket sammen i en alufoliepakning med et tørremiddel.
3 blisters are packed together within a protective aluminium foil wrapper, including a desiccant.
3 blistre á
3 blisters of
3 cm i diameter).
3 cm in diameter).
3 Cox-modelanalyse.
3 Cox model analysis
3 cylinderampuller af 3 ml
3 cartridges of 3 ml
3 dage, kan genoptage behandling med 111 mg én gang dagligt og optitreres til deres optimale dosis.
3 days should be restarted on 111 mg once daily and up-titrated to their optimal dose.
3 Data fra rutinemæssig lægemiddelovervågning: hyppighederne er baseret på erfaringer fra placebokontrollerede kliniske studier.
3 Data derived from routine pharmacovigilance surveillance and frequencies based on placebo- controlled clinical trial experience.
3 Data fra spontane rapporter (ukendt denominator)
3 Spontaneous reports data (unknown denominator)